Program Highlights

Hear from the speakers and session chairs who will be presenting in the following sessions:

 

​Parallel Session 1
Nutrition and Medical Interventions in Linear Growth
​Thursday, March 2, 2017
16:15 – 17:45 
Virginia Stallings, USA

​Session Chair

The expert speakers in this session will present timely updates for treatment of linear growth faltering in infants, children and adults. Both nutritional and drug (growth hormone) interventions will be considered, Clinical trial results of a nutritional intervention considering calories, protein, micronutrients will be reported.   Current practices and outcomes of growth hormone treatment with specific diagnoses, such as for patients with small for gestation age, Silver-Russel syndrome, idiopathic short stature, classic growth hormone deficiency will be presented. The audience will be invited to comment and ask questions at the end of the session.


​Parallel Session 1
Nutrition and Medical Interventions in Linear Growth
​Thursday, March 2, 2017
16:15 – 17:45 
Jan-Maarten Wit, Netherlands​
When is Growth Hormone Indicated? 

Growth hormone (GH) is indicated for formally registered conditions, but several of these are difficult to define (e.g. GH deficiency), and GH appears efficacious in conditions that are not sufficiently prevalent to enable clinical trials. There are still many uncertainties regarding GH treatment, e.g. optimal dosing, definition of poor growth response, and timing of re-testing GH secretion.


​Parallel Session 2
Pre-term Nutrition
​Friday, March 3, 2017
10:30 – 12:00
Hans van Goudoever, Netherlands​

​Session Chair

Pre-term Nutrition has a huge impact on short but also long term health and disease. With over 500.000 infants born preterm in Europe each year, we have to acknowledge this impact.  Short term consequences of the quality of milk with regard to NEC are addressed. As importantly, two lectures will provide the newest insights of the metabolic and cognitive consequences of early nutrition.


​Parallel Session 5
Malnutrition and Growth Impairment in Low and Middle Income Countries
​Friday, March 3, 2017
17:45 – 19:15  
Jan-Maarten Wit, Netherlands​
Assessment of Linear Growth of Children in Low - and Middle Income Countries (LMICs) 

To objectify linear growth in clinical and epidemiological research in LMICs, various indicators can be used, such as height-for-age z-score (HAZ) (continous or categorical), conditional HAZ (accounting for previous heights), the change of HAZ over time (as such or as z-score, using correlation between the first and second HAZ) and length  velocity z-score (0-24 months). Multi-level modeling is preferable when more measurements per individual child are available over time.


​Parallel Session 8
What Determines our Final Adult Height?
​Saturday, March 4, 2017
11:30 – 13:00
Kim Michaelsen, Denmark


​Session Chair

​Conditions during childhood and especially the first 1000 days have marked effects on adult height, which is associated with many health and social aspects.  Two speakers will present global data on secular trends and correlates of adult height. Furthermore, endocrine regulation of childhood linear growth and factors responsible for the high prevalence of stunting seen in many low income countries will be presented. 

Keep Me Updated